Effect of Rufloxacin Upon Non-Specific Immune Defences: In-Vitro, Ex-Vivo and In-Vivo Results

J Antimicrob Chemother. 1994 Oct;34(4):545-53. doi: 10.1093/jac/34.4.545.


This study investigated in-vitro, ex-vivo and in-vivo the immunomodulatory effects of rufloxacin. 0.5 MIC of rufloxacin significantly enhanced human macrophage phagocytosis and increased intracellular killing of Klebsiella pneumoniae in vitro. Pre-incubation of K. pneumoniae with rufloxacin made the bacteria more susceptible to both phagocytosis and intracellular killing by human macrophages than control organisms. Following pre-exposure of macrophages to 0.5 MIC of rufloxacin, there was a significant increase in the intracellular killing of K. pneumoniae compared with the controls, indicating the ability of rufloxacin to cross biological membranes and to remain active within phagocytes. Ex-vivo experiments show that iv administration of rufloxacin in mice lead to an increase in both phagocytic and microbicidal intracellular activity by phagocytes. In-vivo models of experimental infections showed that prophylactic administration of rufloxacin increased the survival of mice after challenge with Candida albicans.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Infective Agents / pharmacology*
  • Candidiasis / microbiology
  • Candidiasis / prevention & control
  • Fluoroquinolones*
  • Humans
  • Immunity, Cellular / drug effects*
  • In Vitro Techniques
  • Klebsiella Infections / immunology
  • Klebsiella Infections / microbiology
  • Klebsiella pneumoniae
  • Macrophages / drug effects
  • Macrophages / immunology
  • Male
  • Mice
  • Phagocytosis / drug effects
  • Quinolones / pharmacology*


  • Anti-Infective Agents
  • Fluoroquinolones
  • Quinolones
  • rufloxacin